PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis
NASDAQ:PBYI - US74587V1070 - Common Stock
5.25 USD
+0.03 (+0.57%)
5.24 USD
-0.01 (-0.19%)
Taking everything into account, PBYI scores 5 out of 10 in our fundamental rating. PBYI was compared to 549 industry peers in the Biotechnology industry. PBYI scores excellent on profitability, but there are some minor concerns on its financial health. PBYI has a bad growth rate and is valued cheaply. These ratings would make PBYI suitable for value investing!
1. Profitability
1.1 Basic Checks
PBYI had positive earnings in the past year.
PBYI had a positive operating cash flow in the past year.
In multiple years PBYI reported negative net income over the last 5 years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
PBYI's Return On Assets of 24.86% is amongst the best of the industry. PBYI outperforms 97.81% of its industry peers.
PBYI has a Return On Equity of 46.27%. This is amongst the best in the industry. PBYI outperforms 98.54% of its industry peers.
Looking at the Return On Invested Capital, with a value of 31.42%, PBYI belongs to the top of the industry, outperforming 99.09% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PBYI is in line with the industry average of 16.25%.
The last Return On Invested Capital (31.42%) for PBYI is above the 3 year average (17.97%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| ROIC | 31.42% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PBYI (20.35%) is better than 94.54% of its industry peers.
PBYI has a better Operating Margin (19.35%) than 94.72% of its industry peers.
In the last couple of years the Operating Margin of PBYI has grown nicely.
The Gross Margin of PBYI (72.33%) is better than 82.33% of its industry peers.
In the last couple of years the Gross Margin of PBYI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.35% | ||
| PM (TTM) | 20.35% | ||
| GM | 72.33% |
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
2. Health
2.1 Basic Checks
PBYI has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PBYI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PBYI has more shares outstanding
PBYI has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.27, we must say that PBYI is in the distress zone and has some risk of bankruptcy.
PBYI has a worse Altman-Z score (-5.27) than 60.84% of its industry peers.
PBYI has a debt to FCF ratio of 1.01. This is a very positive value and a sign of high solvency as it would only need 1.01 years to pay back of all of its debts.
PBYI has a better Debt to FCF ratio (1.01) than 94.72% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that PBYI is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.10, PBYI is not doing good in the industry: 64.12% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for PBYI, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.01 | ||
| Altman-Z | -5.27 |
ROIC/WACC2.88
WACC10.91%
2.3 Liquidity
PBYI has a Current Ratio of 1.73. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
PBYI's Current ratio of 1.73 is on the low side compared to the rest of the industry. PBYI is outperformed by 78.14% of its industry peers.
A Quick Ratio of 1.62 indicates that PBYI should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.62, PBYI is not doing good in the industry: 78.69% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.62 |
3. Growth
3.1 Past
PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 415.79%, which is quite impressive.
The Revenue has grown by 8.63% in the past year. This is quite good.
PBYI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.28% yearly.
EPS 1Y (TTM)415.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%233.33%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%11.25%
3.2 Future
PBYI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.89% yearly.
The Revenue is expected to decrease by -1.09% on average over the next years.
EPS Next Y-17.31%
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
EPS Next 5Y-12.89%
Revenue Next Year-3.32%
Revenue Next 2Y-3.85%
Revenue Next 3Y-2.82%
Revenue Next 5Y-1.09%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.36 indicates a rather cheap valuation of PBYI.
Based on the Price/Earnings ratio, PBYI is valued cheaply inside the industry as 98.18% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.24. PBYI is valued rather cheaply when compared to this.
PBYI is valuated correctly with a Price/Forward Earnings ratio of 15.94.
94.54% of the companies in the same industry are more expensive than PBYI, based on the Price/Forward Earnings ratio.
PBYI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.36 | ||
| Fwd PE | 15.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaper than 98.54% of the companies in the same industry.
99.27% of the companies in the same industry are more expensive than PBYI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.98 | ||
| EV/EBITDA | 3 |
4.3 Compensation for Growth
PBYI has a very decent profitability rating, which may justify a higher PE ratio.
PBYI's earnings are expected to decrease with -17.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
5. Dividend
5.1 Amount
PBYI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.25
+0.03 (+0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.27%
Inst Owner Change7.37%
Ins Owners15.35%
Ins Owner Change0.07%
Market Cap264.44M
Analysts47.5
Price Target4.42 (-15.81%)
Short Float %6.64%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)204.35%
Min EPS beat(2)14.59%
Max EPS beat(2)394.12%
EPS beat(4)4
Avg EPS beat(4)173.94%
Min EPS beat(4)14.59%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)102.62%
EPS beat(12)10
Avg EPS beat(12)105.29%
EPS beat(16)13
Avg EPS beat(16)203.97%
Revenue beat(2)2
Avg Revenue beat(2)1.23%
Min Revenue beat(2)1.23%
Max Revenue beat(2)1.23%
Revenue beat(4)4
Avg Revenue beat(4)6.13%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)2.95%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)4.1%
PT rev (1m)0%
PT rev (3m)-21.21%
EPS NQ rev (1m)-59.09%
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.47%
EPS NY rev (3m)23.11%
Revenue NQ rev (1m)-15%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.36 | ||
| Fwd PE | 15.94 | ||
| P/S | 1.11 | ||
| P/FCF | 5.98 | ||
| P/OCF | 5.96 | ||
| P/B | 2.53 | ||
| P/tB | 4.52 | ||
| EV/EBITDA | 3 |
EPS(TTM)0.98
EY18.67%
EPS(NY)0.33
Fwd EY6.28%
FCF(TTM)0.88
FCFY16.72%
OCF(TTM)0.88
OCFY16.77%
SpS4.73
BVpS2.08
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.86% | ||
| ROE | 46.27% | ||
| ROCE | 39.77% | ||
| ROIC | 31.42% | ||
| ROICexc | 183.86% | ||
| ROICexgc | N/A | ||
| OM | 19.35% | ||
| PM (TTM) | 20.35% | ||
| GM | 72.33% | ||
| FCFM | 18.58% |
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score6
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.01 | ||
| Debt/EBITDA | 0.19 | ||
| Cap/Depr | 1.04% | ||
| Cap/Sales | 0.05% | ||
| Interest Coverage | 5.43 | ||
| Cash Conversion | 77.32% | ||
| Profit Quality | 91.27% | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.62 | ||
| Altman-Z | -5.27 |
F-Score6
WACC10.91%
ROIC/WACC2.88
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)415.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%233.33%
EPS Next Y-17.31%
EPS Next 2Y-26.51%
EPS Next 3Y-17.16%
EPS Next 5Y-12.89%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%11.25%
Revenue Next Year-3.32%
Revenue Next 2Y-3.85%
Revenue Next 3Y-2.82%
Revenue Next 5Y-1.09%
EBIT growth 1Y135.74%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year71.67%
EBIT Next 3Y11.16%
EBIT Next 5YN/A
FCF growth 1Y291%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y43.58%
OCF growth 3Y23.52%
OCF growth 5Y11.7%